RxDoctor Payments Data

Alberto Sastre, MD

General Practice · Ciales, PRNPI 1295702504

Payments from drug & device makers

$2,857in general payments, 2019–2025

Across 62 payments — averaging $46.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • AstraZeneca$687
  • GSK$207
  • Boehringer Ingelheim$181
  • Eli Lilly Export S.A. Puerto Rico Branch$138
  • Johnson & Johnson$47
  • plus $80 from 3 others

What the payments were for

  • Consulting fees$1,50052%
  • Food & beverage$1,33447%
  • Education$231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,857 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,004
Medicare patients
11
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol293$177,195
TrulicityDulaglutide151$150,743
EliquisApixaban124$83,923
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate234$66,502
Stiolto RespimatTiotropium Br/Olodaterol Hcl133$65,309
Trijardy XrEmpaglifloz/Linaglip/Metformin104$59,095
JardianceEmpagliflozin81$53,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$52,942
SynthroidLevothyroxine Sodium905$52,736
JanumetSitagliptin Phos/Metformin Hcl77$47,832
Soliqua 100-33Insulin Glargine/Lixisenatide47$43,420
JanuviaSitagliptin Phosphate63$41,736
Synjardy XrEmpagliflozin/Metformin Hcl59$37,925
TradjentaLinagliptin64$35,024
Spiriva RespimatTiotropium Bromide65$34,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Trijardy Xr, Jardiance, Synjardy Xr, Tradjenta$181$344,275613 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$687$205,381354 claims
MerckJanumet, Januvia, Janumet Xr$1,518$107,580171 claims
GSKTrelegy Ellipta, Anoro Ellipta$207$64,522102 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$26$52,812144 claims
Johnson & JohnsonXarelto$47$21,63734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Ciales

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →